Pagtapyas sa presyo ng mga gamot sa kanser, diabetes, hypertension ikinatuwa ni Angara

By Jan Escosio February 24, 2024 - 12:37 PM

INQUIRER PHOTO

Nagbunga muli ng maganda ang mga isinulong na reporma sa buwis ni Senator Sonny Angara.

“Nagpapasalamat tayo sa paglabas ng panibangong listahan ng 20 na gamot para sa mga sakit tulad ng hypertension, diabetes, high cholesterol at kidney diseases na karaniwang nararanasan ng marami sa ating mga kababayan. Ito ang isa sa maraming benepisyo na naging bunga ng Republic Act 10963 o ang TRAIN (Tax Reform for Acceleration and Inclusion) Law,” ani Angara.

Kamakailan ay inaprubahan ng Food and Drug Administration (FDA) ang value added tax (VAT) exemption ng  20 gamot sa cancer, hypertension, diabetes, kidney disease, mental illness, high cholesterol at tuberculosis.

Ayon kay Angara, sa ngayon higit 2,000 gamot para sa ibat-ibang sakit ang libre na sa VAT dahil sa TRAIN Law at Corporate Recovery and Tax Incentives for Enterprises (CREATE) Law.

Noong nakaraang buwan, inilabas na rin ng Bureau of Internal Revenue (BIR) ang 21 gamot na  inendorso ng FDA para malibre din sa VAT.

“The end goal of all of these actions is to make these lifesaving drugs more accessible to those who need it. This was the goal of the TRAIN and CREATE Laws when it included these provisions on VAT exemptions for select medicines. Taking care of one’s health should not be an option,” sabi pa ni Angara.

Nilinaw din ng senador na mabibigyan pa ng diskuwento ang senior citizens at persons with disabilities (PWDs) sa kanilang mga gamot alinsunod sa iniakda niyang RA 9994 o ang Expanded Senior Citizen’s Act.

 

TAGS: gamot, tax exemptions, gamot, tax exemptions

Disclaimer: The comments uploaded on this site do not necessarily represent or reflect the views of management and owner of Cebudailynews. We reserve the right to exclude comments that we deem to be inconsistent with our editorial standards.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.